Treatment recommendations for radioimmunotherapy in follicular lymphoma: a consensus conference report

References

• Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225–249.
   PubMed Web of Science ®Google Scholar
• Ganti AK, Bociek RG, Bierman PJ, Enke CA, Vose JM, Armitage JO. Follicular lymphoma: expanding therapeutic options. Oncology (Williston Park) 2005;19:213–228.
   PubMed Web of Science ®Google Scholar
• Fisher RI, LeBlanc M, Press OW, Maloney DG, Unger JM, Miller TP. New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol 2005;23:8447–8452.
   PubMed Web of Science ®Google Scholar
• Zevalin (90-Y ibritumomab tiuxetan) US prescribing information. 2009. Available from: http://www.zevalin.com/pdf/Zevalin_PI_website.pdf
   Google Scholar
• Bexxar (tositumomab and iodine I 131 tositumomab) US prescribing information. 2005. Available from: http://us.gsk.com/products/assets/us_bexxar.pdf
   Google Scholar
• Wiseman GA, Kornmehl E, Leigh B, Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials. J Nucl Med 2003;44:465–474.
   PubMed Web of Science ®Google Scholar
• Wahl RL, Zasadny KR, MacFarlane D, Iodine-131 anti-B1 antibody for B-cell lymphoma: an update on the Michigan Phase I experience. J Nucl Med 1998;39:21S–27S.
   PubMed Web of Science ®Google Scholar
• NCCN Clinical Practice Guidelines in Oncology: Non-Hodgkin's Lymphomas v.1.2010. 2010. Available from: http://www.nccn.org/professionals/physicians_gls/PDF/nhl.pdf
   Google Scholar
• Illidge TM. Radioimmunotherapy of lymphoma: a treatment approach ahead of its time or past its sell-by date? J Clin Oncol 2010;28:2944–2946.
   PubMed Web of Science ®Google Scholar
• Bennett JM, Kaminski MS, Leonard JP, Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab. Blood 2005;105:4576–4582.
   PubMed Web of Science ®Google Scholar
• Vose JM, Bierman PJ, Loberiza FR Jr, Bociek RG, Matso D, Armitage JO. Phase I trial of (90)Y-ibritumomab tiuxetan in patients with relapsed B-cell non-Hodgkin's lymphoma following high-dose chemotherapy and autologous stem cell transplantation. Leuk Lymphoma 2007;48:683–690.
   PubMed Web of Science ®Google Scholar
• Zevalin (90-Y ibritumomab tiuxetan) EMEA prescribing information. 2008. Available from: http://www.emea.europa.eu/humandocs/PDFs/EPAR/zevalin/H-547-PI-en.pdf
   Google Scholar
• Gregory S, Leonard J, Vose J, Superior outcomes associated with earlier use: experience with tositumomab and iodine I 131 tositumomab in 1,177 patients with low-grade, follicular, and transformed non-Hodgkin's lymphoma. J Clin Oncol 2005;23(16 Suppl.): Abstract 6561.
   Web of Science ®Google Scholar
• Emmanouilides C, Witzig TE, Gordon LI, Treatment with yttrium 90 ibritumomab tiuxetan at early relapse is safe and effective in patients with previously treated B-cell non-Hodgkin's lymphoma. Leuk Lymphoma 2006;47:629–636.
   PubMed Web of Science ®Google Scholar
• Palanca-Wessels MC, Press OW. Improving the efficacy of radioimmunotherapy for non-Hodgkin lymphomas. Cancer 2010;116:1126–1133.
   PubMed Web of Science ®Google Scholar
• Leonard JP, Coleman M, Kostakoglu L, Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphoma. J Clin Oncol 2005;23:5696–5704.
   PubMed Web of Science ®Google Scholar
• Link BK, Martin P, Kaminski MS, Goldsmith SJ, Coleman M, Leonard JP. Cyclophosphamide, vincristine, and prednisone followed by tositumomab and iodine-131-tositumomab in patients with untreated low-grade follicular lymphoma: eight-year follow-up of a multicenter phase II study. J Clin Oncol 2010;28:3035–3041.
   PubMed Web of Science ®Google Scholar
• Press OW, Unger JM, Braziel RM, Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911. J Clin Oncol 2006;24:4143–4149.
   PubMed Web of Science ®Google Scholar
• Jacobs SA, Swerdlow SH, Kant J, Phase II trial of short-course CHOP-R followed by 90Y-ibritumomab tiuxetan and extended rituximab in previously untreated follicular lymphoma. Clin Cancer Res 2008;14:7088–7094.
   PubMed Web of Science ®Google Scholar
• Hainsworth JD, Spigel DR, Markus TM, Rituximab plus short-duration chemotherapy followed by yttrium-90 ibritumomab tiuxetan as first-line treatment for patients with follicular non-Hodgkin lymphoma: a phase II trial of the Sarah Cannon Oncology Research Consortium. Clin Lymphoma Myeloma 2009;9:223–228.
   PubMedGoogle Scholar
• Kaminski MS, Tuck M, Estes J, 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 2005;352:441–449.
   PubMed Web of Science ®Google Scholar
• Kaminski M, Tuck M, Estes J, Tositumomab and iodine I-131 tositumomab for previously untreated, advanced-stage follicular lymphoma: median 10 year follow-up results. Blood 2009;114(Suppl. 1): Abstract 3759.
   Google Scholar
• Roboz GJ, Bennett JM, Coleman M, Therapy-related myelodysplastic syndrome and acute myeloid leukemia following initial treatment with chemotherapy plus radioimmunotherapy for indolent non-Hodgkin lymphoma. Leuk Res 2007;31:1141–1144.
   PubMed Web of Science ®Google Scholar
• Link B, Kaminiski M, Coleman M, Leonard J. Phase II study of CVP followed by tositumomab and iodine I-131 tositumomab (Bexxar therapeutic regimen) in patients with untreated follicular non-Hodgkin's lymphoma (NHL). J Clin Oncol 2004;22(14 Suppl.): Abstract 6520.
   Web of Science ®Google Scholar
• Mehta DR, Jankowitz RC, Lenzner DE, Land SR, Jacobs SA. Phase II study of short course CHOP-rituximab followed by 90Y-ibritumomab tiuxetan as first-line treatment for follicular lymphoma: extended follow-up and predictors of relapse. J Clin Oncol 2010;28(15 Suppl.): Abstract 8066.
   Web of Science ®Google Scholar
• McLaughlin P, Neelapu S, Fanale M, R-FND followed by radioimmunotherapy for high-risk follicular lymphoma. Blood 2008;112(Suppl. 1): Abstract 3056.
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Tani M, Pulsoni A, Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ). Lancet Oncol 2008;9:352–358.
   PubMed Web of Science ®Google Scholar
• Zinzani P, Tani M, Broccoli A, A phase II trial of R-FM (rituximab, fludarabine and mitoxantrone) chemotherapy followed by yttrium-90 ibritumomab tiuxetan (90Y-IT) for untreated follicular lymphoma (FL) patients. Blood 2009;114(Suppl. 1): Abstract 3743.
   Google Scholar
• Morschhauser F, Radford J, Van HA, Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol 2008;26:5156–5164.
   PubMed Web of Science ®Google Scholar
• Goff L, Summers K, Iqbal S, Quantitative PCR analysis for Bcl-2/IgH in a phase III study of yttrium-90 ibritumomab tiuxetan as consolidation of first remission in patients with follicular lymphoma. J Clin Oncol 2009;27:6094–6100.
   PubMed Web of Science ®Google Scholar
• Morschhauser F, Bischof-Delaloye A, Rohatiner A, Extended follow-up of the international randomized phase 3 First-Line Indolent Trial (FIT) shows durable benefit of 90Y-ibritumomab tiuxetan (Zevalin®) consolidation of first remission in advanced stage follicular non-Hodgkin's lymphoma. Blood 2008;112(Suppl. 1): Abstract 2002.
   PubMed Web of Science ®Google Scholar
• Fisher RI. Overview of Southwest Oncology Group clinical trials in non-Hodgkin lymphoma. S0016. A phase III trial of CHOP vs CHOP + rituximab vs CHOP + iodine131-labeled monoclonal anti-B1 antibody (tositumomab) for treatment of newly diagnosed follicular NHL. Clin Adv Hematol Oncol 2005;3:544–546.
   Google Scholar
• Bachy E, Brice P, Delarue R, Long-term follow-up of patients with newly diagnosed follicular lymphoma in the prerituximab era: effect of response quality on survival–a study from the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2010;28:822–829.
   PubMed Web of Science ®Google Scholar
• Salles GA, Seymour JF, Feugier P, Rituximab maintenance for 2 years in patients with untreated high tumor burden follicular lymphoma after response to immunochemotherapy. J Clin Oncol 2010;28(15 Suppl.): Abstract 8004.
   Web of Science ®Google Scholar
• Horning SJ, Younes A, Jain V, Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab. J Clin Oncol 2005;23:712–719.
   PubMed Web of Science ®Google Scholar
• Kaminski MS, Zelenetz AD, Press OW, Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 2001;19:3918–3928.
   PubMed Web of Science ®Google Scholar
• Witzig TE, White CA, Wiseman GA, Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma. J Clin Oncol 1999;17:3793–3803.
   PubMed Web of Science ®Google Scholar
• Witzig TE, Gordon LI, Cabanillas F, Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2002;20:2453–2463.
   PubMed Web of Science ®Google Scholar
• Wiseman GA, Gordon LI, Multani PS, Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial. Blood 2002;99:4336–4342.
   PubMed Web of Science ®Google Scholar
• Witzig TE, Flinn IW, Gordon LI, Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol 2002;20:3262–3269.
   PubMed Web of Science ®Google Scholar
• Gordon LI, Molina A, Witzig T, Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1/2 study. Blood 2004;103:4429–4431.
   PubMed Web of Science ®Google Scholar
• Fisher RI, Kaminski MS, Wahl RL, Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas. J Clin Oncol 2005;23:7565–7573.
   PubMed Web of Science ®Google Scholar
• Witzig TE, Molina A, Gordon LI, Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan. Cancer 2007;109:1804–1810.
   PubMed Web of Science ®Google Scholar
• Dosik AD, Coleman M, Kostakoglu L, Subsequent therapy can be administered after tositumomab and iodine I-131 tositumomab for non-Hodgkin lymphoma. Cancer 2006;106:616–622.
   PubMed Web of Science ®Google Scholar
• Ansell SM, Ristow KM, Habermann TM, Wiseman GA, Witzig TE. Subsequent chemotherapy regimens are well tolerated after radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for non-Hodgkin's lymphoma. J Clin Oncol 2002;20:3885–3890.
   PubMed Web of Science ®Google Scholar
• Ansell SM, Schilder RJ, Pieslor PC, Antilymphoma treatments given subsequent to yttrium 90 ibritumomab tiuxetan are feasible in patients with progressive non-Hodgkin's lymphoma: a review of the literature. Clin Lymphoma 2004;5:202–204.
   PubMedGoogle Scholar
• Kaminski MS, Radford JA, Gregory SA, Re-treatment with I-131 tositumomab in patients with non-Hodgkin's lymphoma who had previously responded to I-131 tositumomab. J Clin Oncol 2005;23:7985–7993.
   PubMed Web of Science ®Google Scholar
• Wiseman G, Geyer S, Porrata L, Ongoing results of a phase I trial of two sequential doses of Y-90 ibritumomab tiuxetan (Zevalin®) for patients with relapsed low-grade non-Hodgkin lymphoma (NHL). Ann Oncol 2005;16(Suppl. 2): Abstract 333.
   Google Scholar
• Czuczman M, Koryzna A, Mohr A, Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma. J Clin Oncol 2005;23:694–704.
   PubMed Web of Science ®Google Scholar
• Armitage JO, Carbone PP, Connors JM, Levine A, Bennett JM, Kroll S. Treatment-related myelodysplasia and acute leukemia in non-Hodgkin's lymphoma patients. J Clin Oncol 2003;21:897–906.
   PubMed Web of Science ®Google Scholar